Literature DB >> 17693193

Unstable translocation (8;22) in a case of giant cell reparative granuloma.

Anna Johnsson1, Anna Collin, Anders Rydholm, Henryk A Domanski, Fredrik Mertens, Nils Mandahl.   

Abstract

Giant cell reparative granuloma (GCRG) is an uncommon lesion most often affecting the jaw but also the small bones of the hands and feet. GCRG overlaps clinically and radiographically with other giant cell-rich tumors such as giant cell tumor of bone (GCTB) and aneurysmal bone cyst (ABC). In the only case of a cytogenetically investigated GCRG reported previously, a balanced translocation involving chromosomes 4 and X was found. In the present study, chromosome banding and fluorescence in situ hybridization (FISH) analyses were used to characterize the primary lesion and local recurrence of a GCRG in the thumb and skin biopsy of a 45-year-old woman. The skin showed a normal karyotype. Various forms of a dic(8;22) containing 8q, 22q, and smaller or larger parts of 8p were found in both GCRG samples. In addition, ring chromosomes, most often composed of chromosome 11 material, and telomeric associations were found. The latter aberrations were more frequent in the primary lesion. Normal FISH signals were seen when using probes capable of detecting USP6 rearrangements. The variant 8;22 aberrations were interpreted to originate from an unstable dic(8;22)(p23;p11) that gradually evolved into a functionally monocentric chromosome in the dominating subset of cell populations. We conclude that our case of GCRG shared several cytogenetic characteristics with GCTB but none with ABC.

Entities:  

Mesh:

Year:  2007        PMID: 17693193     DOI: 10.1016/j.cancergencyto.2007.04.017

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  1 in total

1.  First report of a solid variant of aneurysmal bone cyst in the os sacrum.

Authors:  Helen Vester; Bernd Wegener; Christoph Weiler; Andrea Baur-Melnyk; Volkmar Jansson; Hans Roland Dürr
Journal:  Skeletal Radiol       Date:  2009-07-15       Impact factor: 2.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.